To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation.~The 23 patients were enrolled in a 3-week regimen with 200mg Camrelizumab given intravenously every 3weeks and 250mg apatinib mesylate qd ，and 850mg/m2 capecitabine d1-14 and 130mg/m2 oxaliplatin given intravenously d1.
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation